Plant ID: NPO9650
Plant Latin Name: Zanthoxylum nitidum
Taxonomy Genus: Zanthoxylum
Taxonomy Family: Rutaceae
NCBI TaxonomyDB:
354528
Plant-of-the-World-Online:
775896-1
Anodyne; Antiphlogistic; Antirheumatic; Carminative; Depurative; Stimulant; Tonic
Australia; Bangladesh; Myanmar; India; Cambodia; Vietnam; China; Laos; Thailand; Taiwan
CA12; CA9; | |
PPARA; | |
GFER; | |
FABP4; THPO; LMNA; FABP5; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.922E-12 | 4.086E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.924E-11 | 5.026E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.757E-09 | 2.072E-05 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.457E-08 | 3.173E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.850E-08 | 5.072E-05 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.468E-08 | 5.723E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.221E-08 | 6.301E-05 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.145E-07 | 3.113E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 4.185E-07 | 3.505E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.254E-06 | 8.274E-04 | CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.254E-06 | 8.274E-04 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.507E-06 | 1.475E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.507E-06 | 1.475E-03 | CYP1A2, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.177E-06 | 2.218E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 6.262E-06 | 3.247E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 8.764E-06 | 4.337E-03 | CYP1A1, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.168E-05 | 5.529E-03 | CYP1A1, CYP1A2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.090E-10 | 2.127E-08 | CYP2D6, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.464E-08 | 6.696E-07 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.824E-07 | 1.824E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.090E-06 | 1.568E-05 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 9.155E-06 | 4.699E-05 | CYP1A2, CYP1A1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.097E-05 | 4.699E-05 | CYP2D6, CYP1A2, CYP3A4 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.097E-05 | 4.699E-05 | FABP4, FABP5, PPARA |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.694E-04 | 1.408E-03 | CYP1A1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.568E-04 | 5.226E-04 | CYP1A2, CYP3A4 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.275E-05 | 1.978E-04 | CA12, CA9 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.246E-03 | 8.853E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
C00-D49: Neoplasms | Cancer | C00-C96 | CA9; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |